Concepedia

Lisa Connery

LC

Statistics

Publications

11

Citations

5.9K

H-Index

10

Active since

1999

Affiliations

Eli Lilly (United States)(Current)

Novo Nordisk (Denmark)

Alliance for Multispecialty Research (United States)

York University

McMaster University

Lisa Connery is an author at Eli Lilly (United States) specializing in pharmacology, pharmacotherapy, and clinical pharmacology.

Publications per year

1999–2025

11

Publications

11

Tirzepatide Once Weekly for the Treatment of Obesity

Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine · 2022 · 3.2K citations · Full text

, , +15

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity

Louis J. Aronne, Naveed Sattar, Deborah B. Horn et al. · JAMA · 2023 · 709 citations · Full text

, , +16

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

, , +16

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi et al. · Diabetes Care · 2019 · 468 citations · Full text

, , +17

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Sean Wharton, Thomas Blevins, Lisa Connery et al. · New England Journal of Medicine · 2023 · 418 citations

, , +17

1–5 of 11